Mainland stocks rose on Friday, but closed the week roughly flat as an earnings lull kept investors cautious ahead of fresh policy signals while Hong Kong shares ended up for the day, but down for the week.

The benchmark Hang Seng Index ended up 192 points, or 0.75 percent, at 25,690 while the Hang Seng Tech Index was up just over 60 points, or 1.12 percent, at 5,479 after hitting a five-month low earlier this week and the Hang Seng China Enterprises Index was up 59 points, or 0.68 percent at 8,901.

The benchmark Shanghai Composite Index was up 14 points, or 0.36 percent, at 3,890 while the Shenzhen Component Index was 86 points, or 0.66 percent, higher at 13,140 and the ChiNext Index, tracking China's Nasdaq-style board of growth enterprises, was 15 points, or 0.49 percent, up at 3,122.

China's blue-chip CSI300 Index gained around 0.3 percent on Friday.

The index was ⁠down 0.3 percent this week, while the Hang Seng fell 1.1 percent. ‍

The CSI Index was largely flat over the past month after a 16 percent rally this year.

Chinese chip stocks were little changed amid reports that the Trump administration had launched a review that could allow the first shipments of Nvidia's second-most powerful artificial intelligence chips to China.

Onshore AI shares rose 0.5 percent.

The CSI Tourism Index rose nearly three percent, with the China Tourism ⁠Group Duty Free surging 8.2 percent, after China launched a US$113 billion free-trade experiment on Hainan.

Nomura analysts said the gap between the property sector and exports is likely to persist, forecasting China's GDP growth at 4.3 percent in 2026, easing to 4.1 percent in the first half before rebounding to 4.5 percent in the second on expected spring stimulus and a lower base.

Healthcare shares traded onshore and offshore rose 1.4 percent and 1.8 percent, respectively.

Shanghai Fosun Pharmaceutical shares ended ⁠2.2 percent higher on the Clavis Bio deal. (Reuters/Xinhua)